FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

FDA Clears Zimmer Biomet Shoulder Baseplate

FDA clears a Zimmer Biomet Holdings 510(k) for its Comprehensive Augmented Baseplate, which is intended to offer an alternative to bone grafting and e...

Human Drugs

FDA Refuses to Review Alkermes NDA for Depression Drug

FDA issues Alkermes a Refusal to File letter on its NDA for New ALKS 5461 (buprenorphine and samidorphan), a once-daily, oral investigational medicine...

Federal Register

How Industry Can Submit Proposed Guidances

Federal Register Final Rule; technical amendment: FDA amends its good guidance practices regulation to inform the public on how to electronically subm...

Federal Register

Workshop on Medical Gas Regulation

Federal Register notice: FDA announces a 5/11 public workshop on medical gas regulation entitled Medical Gas Regulation: Workshop 3.

Human Drugs

Vertice Pharma Petitions FDA on Sucralfate Bioequivalence

Vertice Pharma petitions FDA to revise and make more stringent bioequivalence requirements outlined in its Draft Guidance for Sucralfate Oral Suspensi...

FDA General

Latest Federal Register Notices

FDA Review posts the Federal Register notices for the week ending 3/30/2018.

Federal Register

Workshop on Generic Regulatory Science Initiatives

Federal Register notice: FDA announces a 5/24 public workshop on FY 2018 Generic Drug Regulatory Science Initiatives.

Federal Register

Joint Panel to Discuss Celebrex Safety Data

Federal Register notice: FDA announces a 4/24-25 joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting to ...

Human Drugs

Foundation Medicine Cancer Diagnostic Approved

FDA approves Foundation Medicines FoundationOne CDx (F1CDx), a next generation sequencing-based in vitro diagnostic test that can detect genetic mutat...

Human Drugs

FDA Releases 2 User Fee Implementation Plans

FDA has released two user fee-related implementation plans one on resource capacity and the other on updated benefit-risk assessments.